Livzon Pharmaceutical Secures China Marketing Approval for Traditional Chinese Medicine

MT Newswires Live
10/27

Livzon Pharmaceutical Group (HKG:1513) said China's National Medical Products Administration approved its Wandai Tang Granules for marketing.

The traditional Chinese medicine is used to treat excessive vaginal discharge, according to a Tuesday Hong Kong bourse filings. Developed by the company's subsidiary Sichuan Guangda Pharmaceutical Manufacturing, it is the first product of its kind approved for marketing in China.

The drugmaker said the approval is not expected to have a material impact on its operating results in the near term.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10